[go: up one dir, main page]

WO2005051998A3 - Anticorps - Google Patents

Anticorps Download PDF

Info

Publication number
WO2005051998A3
WO2005051998A3 PCT/EP2004/013426 EP2004013426W WO2005051998A3 WO 2005051998 A3 WO2005051998 A3 WO 2005051998A3 EP 2004013426 W EP2004013426 W EP 2004013426W WO 2005051998 A3 WO2005051998 A3 WO 2005051998A3
Authority
WO
WIPO (PCT)
Prior art keywords
apolipoprotein
terminal fragment
antibodies binding
fragment
binds
Prior art date
Application number
PCT/EP2004/013426
Other languages
English (en)
Other versions
WO2005051998A2 (fr
Inventor
Christer Nordstedt
Tom Goldschmidt
Maria Henderikx
Rene Hoet
Hendricus Hoogenboom
Simon Hufton
Christin V Andersson
Johanna Lindquist
Dan Sunnemark
Sergy Leonov
Original Assignee
Astrazeneca Ab
Dyax Corp
Christer Nordstedt
Tom Goldschmidt
Maria Henderikx
Rene Hoet
Hendricus Hoogenboom
Simon Hufton
Christin V Andersson
Johanna Lindquist
Dan Sunnemark
Sergy Leonov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2004293180A priority Critical patent/AU2004293180B2/en
Priority to EP04819225A priority patent/EP1687336A2/fr
Priority to US10/579,445 priority patent/US7612179B2/en
Priority to JP2006540392A priority patent/JP4869074B2/ja
Priority to CN2004800352575A priority patent/CN1890266B/zh
Priority to CA002547675A priority patent/CA2547675A1/fr
Application filed by Astrazeneca Ab, Dyax Corp, Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, Rene Hoet, Hendricus Hoogenboom, Simon Hufton, Christin V Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov filed Critical Astrazeneca Ab
Priority to BRPI0417023-7A priority patent/BRPI0417023A/pt
Publication of WO2005051998A2 publication Critical patent/WO2005051998A2/fr
Priority to IL175608A priority patent/IL175608A0/en
Priority to NO20063026A priority patent/NO20063026L/no
Publication of WO2005051998A3 publication Critical patent/WO2005051998A3/fr
Priority to US12/585,180 priority patent/US8058016B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un fragment d'anticorps humain. Ledit anticorps ou fragment d'anticorps : (i) se fixe sur un polypeptide comportant la séquence d'acides aminés SEQ ID NO: 1 du domaine C-terminal de l'Apolipoprotéine E (ApoE-CTD) ou la séquence d'acides aminés d'une partie de ce domaine ; (ii) se fixe sur les plaques humaines.
PCT/EP2004/013426 2003-11-28 2004-11-26 Anticorps WO2005051998A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP04819225A EP1687336A2 (fr) 2003-11-28 2004-11-26 Anticorps
US10/579,445 US7612179B2 (en) 2003-11-28 2004-11-26 antibodies binding to a C-terminal fragment of apoliopoprotein E
JP2006540392A JP4869074B2 (ja) 2003-11-28 2004-11-26 抗体
CN2004800352575A CN1890266B (zh) 2003-11-28 2004-11-26 抗体
CA002547675A CA2547675A1 (fr) 2003-11-28 2004-11-26 Anticorps
AU2004293180A AU2004293180B2 (en) 2003-11-28 2004-11-26 Antibodies binding to a C-terminal fragment of Apolipoprotein E
BRPI0417023-7A BRPI0417023A (pt) 2003-11-28 2004-11-26 anticorpo ou fragmento de anticorpo humanos, uso dos mesmos, composição farmacêutica, métodos para tratar um paciente que sofre de um distúrbio amilóide, para diagnosticar um distúrbio amilóide em um paciente, e para detectar a presença do apoe-ctd em uma amostra de um paciente, polinucleotìdeo, vetor, célula hospedeira, vìrus, e, kit para detectar apoe-ctd
IL175608A IL175608A0 (en) 2003-11-28 2006-05-11 Antibodies
NO20063026A NO20063026L (no) 2003-11-28 2006-06-28 Antistoffer
US12/585,180 US8058016B2 (en) 2003-11-28 2009-09-08 Methods of using an antibody that binds to apolipoprotein e

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52517403P 2003-11-28 2003-11-28
US60/525,174 2003-11-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/579,445 A-371-Of-International US7612179B2 (en) 2003-11-28 2004-11-26 antibodies binding to a C-terminal fragment of apoliopoprotein E
US12/585,180 Continuation US8058016B2 (en) 2003-11-28 2009-09-08 Methods of using an antibody that binds to apolipoprotein e

Publications (2)

Publication Number Publication Date
WO2005051998A2 WO2005051998A2 (fr) 2005-06-09
WO2005051998A3 true WO2005051998A3 (fr) 2007-07-26

Family

ID=33564077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/013426 WO2005051998A2 (fr) 2003-11-28 2004-11-26 Anticorps

Country Status (16)

Country Link
US (1) US8058016B2 (fr)
EP (2) EP1687336A2 (fr)
JP (1) JP4869074B2 (fr)
KR (2) KR20060120161A (fr)
CN (1) CN1890266B (fr)
AR (1) AR047729A1 (fr)
AU (1) AU2004293180B2 (fr)
BR (1) BRPI0417023A (fr)
CA (1) CA2547675A1 (fr)
GB (1) GB2408508A (fr)
IL (1) IL175608A0 (fr)
NO (1) NO20063026L (fr)
RU (1) RU2006122946A (fr)
TW (1) TW200530267A (fr)
UY (1) UY28641A1 (fr)
WO (1) WO2005051998A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493433T1 (de) 2002-09-11 2011-01-15 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
AU2004299486B2 (en) * 2003-12-15 2011-05-19 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
ES2610474T3 (es) * 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
JP5622397B2 (ja) 2007-03-12 2014-11-12 エスバテック− ア ノバルティス カンパニー エルエルシー 一本鎖抗体の配列に基づく操作および最適化
NZ581470A (en) 2007-06-25 2013-04-26 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
WO2009033009A2 (fr) 2007-09-05 2009-03-12 Inotek Pharmaceuticals Corporation Anticorps contre la flagelline et leurs utilisations
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN110082533B (zh) 2008-04-09 2023-01-10 健泰科生物技术公司 用于免疫相关疾病的治疗的新组合物和方法
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde
AU2011336360A1 (en) * 2010-12-02 2013-07-04 The Washington University Compositions and methods for treating amyloid plaque associated symptoms
CN102863525B (zh) * 2011-07-04 2014-06-04 武汉大学 一种重组人apoE拟肽及制备方法和应用
HRP20201404T1 (hr) 2013-07-16 2020-11-27 F. Hoffmann - La Roche Ag Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
TWI811892B (zh) 2015-09-25 2023-08-11 美商建南德克公司 抗tigit抗體及使用方法
HRP20220436T1 (hr) * 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
EP3532034A4 (fr) 2016-10-28 2020-12-02 Washington University Anticorps anti-apoe
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3597222A1 (fr) * 2018-07-16 2020-01-22 Easemedcontrol R & D GmbH & Co KG Traitement et diagnostic de maladies inflammatoires non résolues
CN113631566A (zh) 2019-02-08 2021-11-09 路博润先进材料公司 可用于对皮肤、毛发、指甲和/或粘膜进行处理和/或护理的化合物
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
AU2020282792A1 (en) * 2019-05-28 2021-12-23 Banner Health ApoE antibodies, fusion proteins and uses thereof
EP3757121A1 (fr) * 2019-06-28 2020-12-30 Eisai R&D Management Co., Ltd. Fragments d'apolipoprotéine e
CA3172976A1 (fr) * 2020-03-27 2021-09-30 Epivax, Inc. Epitopes de lymphocytes t regulateurs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2148116T1 (es) * 1992-10-13 2000-10-16 Univ Duke Metodos de detectar la enfermedad de alzheimer.
US6107045A (en) 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
US6428950B1 (en) * 1998-11-25 2002-08-06 Scios Inc. Assay to identify compounds that alter apolipoprotein E expression
JP4399160B2 (ja) * 2000-11-03 2010-01-13 ザ ジェイ． デビッド グラッドストーン インスティテューツ ａｐｏＥに関連する疾患を治療する方法
AU2002222308A1 (en) * 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular response
WO2003031971A1 (fr) * 2001-10-04 2003-04-17 Immuno-Biological Laboratories Co., Ltd. Reactif pour detecter un facteur de risque de la maladie d'alzheimer, necessaire de detection a cet effet, et procede de detection du facteur de risque de la maladie d'alzheimer au moyen de ce necessaire
US7682795B2 (en) 2002-07-30 2010-03-23 The J. David Gladstone Institutes Method of diagnosing Alzheimer's Disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding" IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, September 1996 (1996-09), pages 169-179, XP004070292 ISSN: 1380-2933 *
FUJITA S C ET AL: "Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain" NEUROSCIENCE RESEARCH 1999 IRELAND, vol. 35, no. 2, 1999, pages 123-133, XP008046267 ISSN: 0168-0102 *
HYUN SOON CHO ET AL: "QUANTITATION OF APOE DOMAINS IN ALZHEIMER DISEASE BRAIN SUGGESTS A ROLE FOR APOE IN ASS AGGREGATION" JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 160, no. 4, April 2001 (2001-04), pages 342-349, XP001018640 ISSN: 0022-3069 *
SADOWSKI M ET AL: "Inhibition of apolipoprotein E binding to amyloid - beta decreases fibril formation and deposition in vitro and in vivo." SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, pages Abstract No. 666.6 URL-http://sf, XP008047558 & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003 *
See also references of EP1687336A2 *
YAMADA T ET AL: "Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits" ANNALS OF CLINICAL AND LABORATORY SCIENCE, INSTITUTE FOR CLINICAL SCIENCE, PHILADELPHIA, PA, US, vol. 27, no. 4, July 1997 (1997-07), pages 276-281, XP002978336 ISSN: 0091-7370 *
YAMADA TOSHIYUKI ET AL: "A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposits" ANNALS OF CLINICAL AND LABORATORY SCIENCE, vol. 24, no. 3, 1994, pages 243-249, XP008046338 ISSN: 0091-7370 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
CN1890266B (zh) 2012-10-03
BRPI0417023A (pt) 2007-02-21
EP1687336A2 (fr) 2006-08-09
NO20063026L (no) 2006-08-28
WO2005051998A2 (fr) 2005-06-09
EP2343318A3 (fr) 2013-02-27
JP4869074B2 (ja) 2012-02-01
CA2547675A1 (fr) 2005-06-09
TW200530267A (en) 2005-09-16
CN1890266A (zh) 2007-01-03
AR047729A1 (es) 2006-02-15
UY28641A1 (es) 2005-06-30
EP2343318A2 (fr) 2011-07-13
JP2008502311A (ja) 2008-01-31
KR20060120161A (ko) 2006-11-24
AU2004293180B2 (en) 2011-09-15
GB0426043D0 (en) 2004-12-29
AU2004293180A1 (en) 2005-06-09
US20100061993A1 (en) 2010-03-11
GB2408508A (en) 2005-06-01
KR20120108061A (ko) 2012-10-04
US8058016B2 (en) 2011-11-15
IL175608A0 (en) 2006-09-05
RU2006122946A (ru) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2005051998A3 (fr) Anticorps
WO2007002261A3 (fr) Anticorps bloquant il-1$g(b) et leurs fragments
JP2003515323A5 (fr)
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
IL163066A (en) Ligands for the zcytor17 receptor
EP3300739A3 (fr) Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2005087811A3 (fr) Recepteurs des oestrogenes et procedes d'utilisation associes
WO2002018443A3 (fr) Anticorps monoclonal de recombinaison dirige contre les proteines contenant de la phosphotyrosine
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2002101052A3 (fr) Salutaridinol 7-o-acetyltransferase et derives de celle-ci
WO2006127822A3 (fr) Polypeptides associes au domaine 1 de scytovirine
ATE466876T1 (de) Immunogene konstrukte
WO2001002429A3 (fr) Angiopoietine 6 et ses utilisations
CA2385766A1 (fr) Methodes de production de proteines dans des cellules hotes
WO2003025179A1 (fr) Nouveau polypeptide, adn associe et utilisation de ce polypeptide
WO2006038101A3 (fr) Nouveaux anticorps et antigenes associes au cancer et leur utilisation dans le diagnostic du cancer
WO2007073845A3 (fr) Nouveau polypeptide presentant une activite d'esterase, esterase recombinee et leur utilisation
WO2002072753A3 (fr) Peptides de thymidylate synthase se fixant a l'arnm de la thymidylate synthase
WO2003027150A1 (fr) Anticorps et son utilisation
WO2006125914A3 (fr) Utilisation de la protéine h11 dans le diagnostic in vitro d'infections à streptococcus pyogenes.
WO2004069989A3 (fr) Nouveaux polypeptides de phosphodiesterase purifies
WO2004058811A3 (fr) Structures cristallines des polypeptides yhhf
NZ631185A (en) Prlr-specific antibody and uses thereof
NZ606260A (en) Novel polypeptides involved in immune response

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480035257.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12006500881

Country of ref document: PH

Ref document number: 546935

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200603671

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 175608

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004819225

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005906

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004293180

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067010370

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2547675

Country of ref document: CA

Ref document number: 2006540392

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2004293180

Country of ref document: AU

Date of ref document: 20041126

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004293180

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06062058

Country of ref document: CO

Ref document number: 3699/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006122946

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004819225

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007104715

Country of ref document: US

Ref document number: 10579445

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067010370

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0417023

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10579445

Country of ref document: US